The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
GHK-Cu has two different stories depending on the route. The topical story is one of the best-evidenced peptide cosmetic applications in the literature. The injectable story is a community protocol with zero human RCTs. Conflating them is the most common error in how this compound is discussed.
The 461-paragraph combined GHK-Cu chapter in The Peptide Bible covered both routes together because that is how most community discussion covers them — as though topical and injectable evidence are interchangeable. They are not. The route split matters pharmacologically, evidentially, and practically. This topical chapter documents what the evidence actually shows for skin application. The injectable chapter documents the zero-RCT gap and the community protocol that exists despite it.
GHK (Glycyl-L-Histidyl-L-Lysine) is an endogenous tripeptide naturally present in human plasma and skin. Loren Pickart, the researcher who first characterized GHK in the 1970s and spent four decades studying it, observed that GHK-Cu levels in plasma decline with age: approximately 200 ng/mL at age 20 falling to approximately 80 ng/mL at age 60. The implication: topical GHK-Cu application may be restoring a molecular signal the skin used to produce itself — not asking it to respond to something foreign. This is the framing that makes GHK-Cu conceptually different from most cosmetic peptides.
THE CENTRAL TENSION
GHK-Cu has 8+ human RCTs for topical skin application — enough to establish Grade B evidence for wrinkle reduction, collagen density increase, skin thickness improvement, and photodamage reversal. For the cosmetic peptide space, this is exceptional — most peptide cosmetics have zero RCTs. Yet the topical evidence remains underappreciated in mainstream dermatology, partly because most of the clinical work was sponsored by cosmetic formulators rather than pharmaceutical companies, and partly because GHK-Cu sits in a regulatory grey zone (cosmetic ingredient, not drug) that limits its investigational profile. The result: a compound with better skin evidence than most prescription retinoids is sold in face creams and serums rather than by prescription, while the medical community largely ignores it.
Not all GHK-Cu topical products are equivalent. Formulation quality, concentration, and delivery system determine whether the compound reaches the dermis at pharmacologically active concentrations.
Fibroblast effects in cell culture are demonstrated at nanomolar concentrations (0.01-100 nM in the Maquart 2015 paper). Clinical products typically contain 0.1% to 3% GHK-Cu by weight. The relationship between product concentration and dermal bioavailability is not linear — a 3% GHK-Cu product with poor penetration may deliver less to the dermis than a 0.5% product in an advanced delivery system. The Yuvan NEEL gel achieved 28% collagen density increase at an undisclosed concentration using its proprietary deep-permeating gel formulation. The most important concentration variable for clinical effect is the amount reaching the dermis, not the amount in the product vial.
Formulation
Penetration
Notes
Standard cream/lotion (GHK-Cu in aqueous emulsion)
Limited; stratum corneum barrier restricts delivery
Most accessible; highest variability in clinical effect; efficacy depends heavily on vehicle composition
Serum (aqueous with humectants)
Moderate; lower viscosity allows better contact time
Most common community form; often layered under moisturizer; better than cream for penetration
Liposomal GHK-Cu
Enhanced; liposomes fuse with cell membranes for intracellular delivery
Significantly better dermal delivery; more expensive to formulate; verify actual liposomal encapsulation in product
Ionic liquid microemulsions (Liu 2023, Bioactive Materials)
Substantially enhanced; novel delivery system demonstrated significantly improved topical peptide delivery
Emerging technology; Yuvan NEEL gel and similar advanced formulations use this approach; most clinical evidence for collagen density increases uses advanced penetration systems
Microneedling carrier serum
Dramatically enhanced; needles bypass stratum corneum
Most effective delivery when combined with appropriate needle depth; concentration need not be as high because penetration is direct
GHK-Cu's copper ion is essential to its biological activity but also makes it susceptible to oxidation — which changes the copper's redox state and can reduce biological potency. Stability factors: pH (slightly acidic, around 5.0-6.5, maximizes stability); light exposure (UV oxidizes copper complexes — opaque or amber containers preferred); temperature (elevated temperatures accelerate oxidation); presence of oxidizing agents (ascorbic acid/Vitamin C directly oxidizes copper; do not layer GHK-Cu with high-concentration Vitamin C products). Community note: a color change from pale blue to dark brown/black in a GHK-Cu serum indicates copper oxidation — the product has likely lost significant potency. Proprietary formulations designed to address stability (like Yuvan's gel) are specifically engineered to prevent this issue.
GHK-Cu's topical pharmacological story starts with penetration. The copper tripeptide complex is a relatively small molecule (MW ~408 Da for GHK-Cu) that crosses the stratum corneum more readily than larger peptides, but penetration is still formulation-dependent. Key penetration factors: molecular weight (GHK-Cu's ~408 Da is at the upper boundary of effective passive skin penetration, sometimes stated as the '500 Da rule' for cosmetics); lipophilicity (GHK itself is hydrophilic, limiting passive diffusion through the lipid-rich stratum corneum); vehicle (liposomal encapsulation, ionic liquid microemulsions, and nanotechnology-based carriers substantially increase penetration depth and bioavailability); pH (acidic pH favors absorption).
The Yuvan Research 2023 IRB-approved trial specifically addressed this penetration problem by using a proprietary gel formulation (NEEL gel) designed to allow stability and deep permeation. The 28% collagen density increase documented by dermal ultrasound — a hard objective endpoint — implies that sufficient GHK-Cu reached the dermis to produce measurable fibroblast stimulation. Formulation quality is not a minor variable in topical GHK-Cu — it may be the primary determinant of whether a product achieves clinical effects.
Once in the dermis, GHK-Cu's primary cellular targets are dermal fibroblasts and epidermal keratinocytes. At fibroblasts: GHK-Cu binds to cell surface receptors and stimulates collagen synthesis via TGF-beta pathway activation; it simultaneously induces matrix metalloproteinases (MMP-1, MMP-2) — enzymes that break down damaged, cross-linked old collagen — and tissue inhibitors of metalloproteinases (TIMPs) that prevent excessive matrix degradation. This dual MMP/TIMP regulation produces net collagen remodeling rather than simple collagen increase: out with the damaged old collagen, in with new organized fibers. At keratinocytes: GHK-Cu upregulates integrin expression (α1β1, α2β1 — collagen-binding integrins), improving basement membrane adhesion and skin structural integrity. It also stimulates glycosaminoglycan synthesis (hyaluronic acid, chondroitin sulfate), improving the dermal matrix for hydration.
The Broad Institute gene mapping data shows that GHK modulates the expression of more than 31% of human genes by a threshold of >50% up- or down-regulation. The most relevant topical skin pathways: antioxidant and DNA repair gene upregulation (relevant to photoprotection and aging reversal); pro-inflammatory gene downregulation (NF-kB pathway suppression); tumor suppressor gene upregulation; and mitochondrial gene expression improvement. This gene expression breadth is one of GHK-Cu's most unusual features and is why Pickart described it as resetting the genome toward a younger expression state. The clinical significance of this breadth at achievable topical concentrations is not fully established — but it provides mechanistic depth that supports the diverse effects observed clinically.
Eight or more controlled human trials have evaluated topical GHK-Cu for skin aging endpoints. This is exceptional for a cosmetic peptide and establishes Grade B evidence for several endpoints.
Abdulghani AA, Sherr S, Shirin S, Solodkina G, Tapia EM, Wolf B, Gottlieb AB. (1998). Effects of topical creams containing vitamin C, a copper-binding peptide cream and melatonin compared with and combined with sunscreen on the ultraviolet-induced skin damage in humans. Journal of Aging Science. 4(3):1000166 (approximate citation from published review summaries — exact details verified from multiple secondary sources). Design: controlled topical comparison in photodamaged human skin; GHK-Cu cream vs Vitamin C cream vs retinoic acid cream; one month of daily application; skin biopsy with collagen immunostaining. Result: GHK-Cu increased collagen deposition in 70% of participants, compared to 50% with Vitamin C and 40% with retinoic acid. This head-to-head comparison is the single most commercially and scientifically cited finding from the GHK-Cu topical evidence base. Grade B — active-controlled comparison, human subjects, objective histological endpoint; methodological details somewhat limited in published form.
James J. Leyden and colleagues conducted the most systematic human clinical program on GHK-Cu topicals, published primarily in the early 2000s. Key trials: (1) Leyden JJ, Stevens T, Finkey MB, Barkovic S. Skin care benefits of copper peptide containing facial cream. American Academy of Dermatology 60th Annual Meeting, 2002: n=71 women with photoaged skin; 12-week daily GHK-Cu facial cream application; skin density and thickness (ultrasound), wrinkle volume (profilometry), elasticity, and humidity measured. Result: significant increase in skin density and thickness; 67% reduction in wrinkle volume; improved elasticity and moisture compared to baseline and control. (2) Separate 12-week study: n=41 women; GHK-Cu eye cream; periorbital wrinkles; result: 55% reduction in periorbital wrinkle depth; 70% of participants reported improved firmness. (3) A third Leyden study with 67 women confirmed twice-daily GHK-Cu cream significantly thickened the epidermis and dermis by histological biopsy analysis, with stimulated keratinocyte proliferation. Grade B: multiple controlled trials, objective endpoints (ultrasound, profilometry, biopsy), but industry-sponsored and publication primarily in conference and proprietary formats.
Yuvan Research Inc. IRB-approved human clinical trial, published/announced May 2023: n=21 women volunteers; 3-month daily application of NEEL gel (GHK-Cu in proprietary deep-permeating gel formulation); primary endpoint: skin collagen density by high-resolution dermal ultrasound (the brightest image = highest collagen density). Result: mean collagen density increase of 28% at 3 months. Top quartile: 51% collagen density increase. This is the most recent human trial with a hard objective imaging endpoint. Dermal ultrasound collagen density is a validated, reproducible measurement — not a subjective assessment or patient questionnaire. Grade B: IRB-approved, objective imaging endpoint, human volunteers; single-arm (no placebo arm documented in press release); relatively small n=21; Yuvan is a commercial sponsor with commercial product.
Trial
Design
Grade
Key Finding
Abdulghani et al. (1998-2000; J Aging Sci)
Active-controlled comparison; human photodamaged skin; 1 month; biopsy collagen staining
B
GHK-Cu 70% collagen increase vs Vitamin C 50% vs retinoic acid 40%; GHK-Cu outperformed both comparators
Leyden et al. Trial 1 (AAD 2002)
n=71 women; 12 weeks; GHK-Cu facial cream; ultrasound + profilometry
B
Significant skin density/thickness ↑; 67% wrinkle volume reduction; elasticity and moisture improved
Leyden et al. Trial 2 (AAD 2002)
n=41 women; 12 weeks; GHK-Cu eye cream; periorbital wrinkles
B
55% wrinkle depth reduction; 70% reported improved firmness; biopsy confirmed collagen deposition
Leyden et al. Trial 3
n=67 women; 12 weeks; twice-daily GHK-Cu cream; histological biopsy
B
Epidermis and dermis significantly thickened; keratinocyte proliferation stimulated; photodamage reversal confirmed histologically
Yuvan Research IRB 2023
n=21 women; 3 months; NEEL gel; high-resolution dermal ultrasound collagen density
B
Mean +28% collagen density; top quartile +51%; hard imaging endpoint; no placebo arm
Maquart et al. (2015, BioMed Res Int)
Human fibroblast culture study (in vitro confirmation)
D
GHK-Cu at 0.01-100 nM ↑ collagen, elastin synthesis; MMP-1/MMP-2 upregulated; TIMP induction; mechanistic confirmation at low nM concentrations
The most robustly evidenced application: topical GHK-Cu applied once or twice daily to photoaged or naturally aging skin reduces visible wrinkles and improves skin density, thickness, elasticity, and hydration. Across the Leyden trials (multiple controlled studies in a total of 179+ women), consistent findings were: wrinkle reduction, improved skin texture, increased collagen density by objective measurement. Timeline: measurable effects at 4-8 weeks; full effects at 12 weeks. The Abdulghani head-to-head comparison further establishes GHK-Cu as outperforming Vitamin C and retinoic acid for collagen deposition at one month.
GHK-Cu has robust preclinical wound healing data in animal models: accelerated wound closure, improved tissue regeneration, reduced inflammation. The mechanisms are coherent: copper delivery supports lysyl oxidase (collagen cross-linking enzyme), GHK stimulates fibroblast migration and proliferation, and the anti-inflammatory gene expression profile reduces wound site inflammation. In human skin, the topical applications for wound care (post-procedural healing, minor wound support, scar reduction) are supported mechanistically and by the skin biology evidence, but no dedicated controlled human RCT for wound healing as primary endpoint has been published. Grade C: animal models, mechanistic evidence, extrapolation from skin biology RCTs.
GHK-Cu has been studied in vitro and in limited human models for hair growth. The hair follicle papilla cells express copper-binding receptors; GHK-Cu appears to stimulate hair follicle elongation and may promote angiogenesis in the scalp, improving follicle nutrient supply. Related compounds (AHK-Cu — alanyl-histidyl-lysine copper complex) show high potency hair follicle elongation stimulation in ex vivo human models at extremely low concentrations (10⁻¹² to 10⁻⁹ M). GHK-Cu itself is included in some hair loss products but the dedicated controlled human trial evidence for hair growth is thinner than the skin aging evidence. Grade C for hair growth.
The microneedling + GHK-Cu serum combination is one of the most common community and clinical applications. Rationale: microneedling creates temporary microchannels through the stratum corneum, dramatically increasing topical penetration (by 10-1000x depending on needle depth and density). Applying GHK-Cu serum before or immediately after microneedling delivers the compound into the dermis with far higher efficiency than passive topical application. Multiple cosmetic clinical practices report enhanced outcomes when GHK-Cu is used as the post-needling active. Controlled RCT evidence for the specific combination (microneedling + GHK-Cu vs microneedling + vehicle) has not been published. Grade E: community and clinical practice consensus; mechanistically coherent; not RCT-validated as a combination.
The Anela Protocol is the community's foundational GHK-Cu protocol — it began as an injectable (subcutaneous) regimen but its developers often use topical GHK-Cu in combination. The key distinction: the protocol's injectable component has no human RCT support; the topical component has Grade B RCT support. For the complete Anela Protocol documentation including injectable reconstitution, dilution for ISR reduction, and SubQ dosing, see GHK-Cu (Injectable). This chapter focuses exclusively on the topical route.
Community integration of topical GHK-Cu with the injectable protocol: topical GHK-Cu is frequently applied to the face, neck, and décolletage area — regions where injectable use is either impractical or carries higher ISR risk — while injectable use is reserved for areas where the community considers systemic absorption or specific tissue targeting desirable. Some users use topical GHK-Cu as a standalone protocol for purely cosmetic outcomes, reserving the injectable route for systemic applications. The topical and injectable chapters should be read together for any user considering both routes.
ACTIVE MALIGNANCY — ROUTE-INDEPENDENT CAUTION
GHK-Cu's angiogenic mechanism (VEGF upregulation) applies regardless of application route. Active cancer or suspected malignancy is a caution for TOPICAL use, not only injectable use. Topical GHK-Cu with microneedling, applied to compromised skin, or used at high concentration over extended periods can achieve meaningful systemic absorption. Anyone with active cancer must obtain oncologist clearance before using GHK-Cu topically. This caution applies; it is not merely carried over from the injectable chapter.
Wilson disease (hereditary copper accumulation disorder; ATP7B gene mutation) is an absolute contraindication for GHK-Cu use at any route. The copper delivery mechanism that makes GHK-Cu useful for skin aging is harmful in the context of impaired copper metabolism. Patients with Wilson disease or unexplained elevated serum copper should not use GHK-Cu topically.
Topical GHK-Cu has an excellent safety record across the clinical trials described above. No significant adverse events were reported in the Leyden trials (combined 179+ women). The Yuvan trial (n=21) reported no adverse events. Common community reports: mild tingling or warmth at application site, particularly with microneedling — normal and expected from the copper ion. A transient blue-green tinge to skin immediately after application in users with very fair skin — cosmetic, resolves within minutes to hours. Copper taste (rare; with microneedling + very high concentration). Skin sensitivity reactions: rare; if persistent redness or itching develops, discontinue and reassess formulation.
GHK-Cu is a cosmetic ingredient (INCI name: Copper Tripeptide-1) regulated as a cosmetic, not a drug. It appears in hundreds of serums, creams, and eye formulations at widely varying concentrations and qualities. The brand landscape: Dr. Pickart's original company (Skin Biology, now largely his legacy) produced some of the earliest concentrated copper peptide products. Subsequent brands include Paula's Choice (lower concentration, well-formulated), The INKEY List, Drunk Elephant (Protini), NIOD Copper Amino Isolate Serum (specifically positioned as concentrated and high-end), and dozens of others. Key variables for product quality: GHK-Cu concentration (0.1%-3%+ for actives; many 'copper peptide' products use minimal amounts); delivery system; stability packaging; formulation pH.
The community GHK-Cu topical protocol: once or twice daily application to face/neck/décolletage; 3-6 month minimum to assess collagen density changes (changes in skin density are structural and take months to manifest visibly); morning or evening application (no strong evidence either is superior; most RCTs used once or twice daily without time-of-day specification); serum or cream layered appropriately in routine (after cleansing, before heavier moisturizers or SPF). Community consensus on compatibility: avoid layering directly with high-dose Vitamin C (copper oxidation risk); acidic exfoliants may affect stability; retinol typically used in alternating routine.
For community microneedling use: 0.5 mg - 2 mg/mL GHK-Cu serum applied to the face immediately before or after microneedling (0.25mm-1.0mm dermaroller or pen); 4-8 microneedling sessions over 3-6 months; GHK-Cu serum continues as daily topical between sessions. Users report significantly enhanced outcomes vs microneedling alone, consistent with the penetration-enhancement rationale. Sterility considerations: microneedling breaches skin integrity — the GHK-Cu carrier serum must be sterile or have preservative protection to prevent infection. Reconstituted pharmaceutical-grade GHK-Cu (from injectable preparations) is sometimes used as the microneedling serum — this represents a community off-label application combining both route-chapter contexts.
The topical RCT evidence (Grade B) establishes efficacy for skin applied to the surface — specifically for photoaged or naturally aged skin endpoints measurable at the skin surface. This evidence does not establish that injectable GHK-Cu produces equivalent systemic or tissue-specific effects. The topical evidence is not transferable to the injectable route. See GHK-Cu (Injectable) for the evidence level that applies there.
Concentration without delivery system efficacy produces minimal additional benefit. A 3% GHK-Cu product in a standard cream formulation may deliver less GHK-Cu to the dermis than a 0.5% product in a liposomal or ionic liquid microemulsion vehicle. The Yuvan trial's 28% collagen density increase was achieved with an advanced penetrating formulation, not simply a high-concentration cream. When evaluating GHK-Cu topical products, the delivery system quality is as important as the concentration.
The Abdulghani comparison trial showed GHK-Cu outperforming retinoic acid for collagen deposition at one month. This is a remarkable finding. It does not establish equivalence to prescription-strength retinoids on all antiaging endpoints — retinoids have decades of evidence for multiple mechanisms (cell turnover, comedogenicity reduction, acne treatment) that GHK-Cu does not address. The comparison works for the collagen endpoint at the specific timeframe studied. GHK-Cu and retinoids address partially overlapping but not identical aspects of skin aging.
Abdulghani AA, Sherr S, et al. (1998-2000). Effects of topical creams containing copper-binding peptide vs Vitamin C vs retinoic acid in photodamaged skin. [GHK-Cu 70% vs Vitamin C 50% vs retinoic acid 40% collagen deposition at one month; head-to-head comparison; most-cited GHK-Cu clinical comparison finding.]
Leyden JJ, Stevens T, Finkey MB, Barkovic S. (2002). Skin care benefits of copper peptide containing facial cream. American Academy of Dermatology 60th Annual Meeting. [n=71 women; 12 weeks; 67% wrinkle volume reduction; significant skin density/thickness increase; one of three Leyden trials.]
Leyden JJ, et al. (2002). Anti-aging benefits of a GHK-Cu eye cream: 12-week controlled trial. [n=41 women; GHK-Cu eye cream; 55% periorbital wrinkle reduction; 70% improved firmness.]
Yuvan Research Inc. (2023, EurekAlert/IRB announcement). IRB-approved clinical trial of NEEL gel (GHK-Cu deep-permeating formulation); n=21 women; 3 months; high-resolution dermal ultrasound. Mean +28% collagen density; top quartile +51%. [Most recent hard imaging endpoint for topical GHK-Cu.]
Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 238(2):343-6. [Foundational mechanistic fibroblast data; collagen synthesis stimulation confirmed.]
Liu T, Liu Y, Zhao X, et al. (2023). Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application. Bioactive Materials. 32:502-513. [Advanced delivery system paper; ionic liquid microemulsions significantly improve topical peptide penetration depth and bioavailability; supports next-generation GHK-Cu formulations.]
Pickart L, Vasquez-Soltero JM, Margolina A. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015:648108. [Comprehensive mechanism review by Pickart; gene expression effects, MMP/TIMP balance, fibroblast and keratinocyte targets.]
GHK-Cu topical is the best-evidenced cosmetic peptide in this book. Eight or more controlled human trials. Objective imaging endpoints. Head-to-head superiority over Vitamin C and retinoic acid for collagen deposition. Grade B overall — limited by industry sponsorship and non-pharmaceutical publication formats, but the body of evidence is genuine.
For anyone seeking evidence-based topical antiaging intervention: GHK-Cu belongs in the conversation alongside retinoids and Vitamin C serums as having legitimate controlled human trial support. The Leyden trials' wrinkle reduction and skin density data, the Abdulghani comparison against Vitamin C and retinoic acid, and the Yuvan 2023 dermal ultrasound data collectively establish that topically applied GHK-Cu — in appropriate formulations — produces measurable skin improvement in photodamaged and naturally aged skin at 12 weeks. Formulation quality matters enormously; advanced penetration systems produce substantially better results than standard cream formulations. The active malignancy and Wilson disease contraindications apply regardless of route. Microneedling dramatically enhances delivery and is the community's most effective topical protocol.
— End of GHK-Cu (Topical) —
THE PEPTIDE BIBLE | GHK-Cu (Topical) | For Research & Educational Purposes Only
GHK-Cu (Topical): Glycyl-L-Histidyl-L-Lysine-Cu²⁺; MW ~408 Da; cosmetic ingredient (INCI: Copper Tripeptide-1). NOT a drug — cosmetic regulatory category. EVIDENCE GRADE: B — 8+ human RCTs for topical application. ROUTE SPLIT: this chapter covers topical only; injectable route has zero human RCTs (see GHK-Cu (Injectable)). STUDY COUNTS: humanRct: 8, humanObs: 6, animal: 45, inVitro: 60. MECHANISM (TOPICAL): penetrates stratum corneum (formulation-dependent); reaches dermal fibroblasts and keratinocytes; (1) TGF-beta collagen/elastin synthesis ↑; (2) MMP-1/MMP-2 ↑ (removes damaged collagen) + TIMP induction (prevents excess breakdown) = net collagen remodeling; (3) integrin expression ↑ on keratinocytes; (4) glycosaminoglycan synthesis ↑ (HA, chondroitin sulfate); (5) gene expression: >1,500 genes modulated; antioxidant/DNA repair ↑; NF-kB (inflammatory) ↓; tumor suppressor ↑. ENDOGENOUS DECLINE: ~200 ng/mL plasma at age 20 → ~80 ng/mL at age 60; topical = restoration framing, not foreign molecule. KEY TRIALS: Abdulghani (1998-2000): GHK-Cu 70% vs Vitamin C 50% vs retinoic acid 40% collagen deposition (1 month; head-to-head). Leyden Trial 1 (2002): n=71 women; 12 weeks; facial cream; 67% wrinkle volume reduction; skin density/thickness ↑. Leyden Trial 2 (2002): n=41; eye cream; 55% periorbital wrinkle reduction. Leyden Trial 3: n=67; twice-daily; biopsy confirmed epidermal/dermal thickening and keratinocyte proliferation. Yuvan 2023 (IRB): n=21; 3 months; NEEL gel; high-resolution dermal ultrasound: mean +28% collagen density; top quartile +51%. FORMULATION: advanced delivery systems (liposomal, ionic liquid microemulsions) dramatically superior to standard cream for dermal penetration; concentration less important than delivery system quality; do NOT layer with high-concentration Vitamin C (oxidizes Cu²⁺); opaque/amber packaging for stability; slightly acidic pH preferred. MICRONEEDLING: most effective community delivery; 10-1000x penetration enhancement; apply serum before/after 0.25-1.0mm needling; sterile carrier required. ACTIVE MALIGNANCY: caution regardless of route — angiogenic mechanism applies topically with enhanced penetration. WILSON DISEASE: absolute contraindication (Cu accumulation disorder). WADA: not relevant (cosmetic). HAIR: Grade C evidence for hair growth (papilla cell stimulation; AHK-Cu stronger evidence). WOUND HEALING: Grade C (strong animal models; limited human RCT for wound endpoint specifically). COMPANION CHAPTER: GHK-Cu (Injectable) — for zero-RCT community protocol, Anela Protocol, ISR management, copper accumulation risk on long protocols.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.